Mindpeak selected as one of the top 10 German Startups

April 16, 2020
Mindpeak is already one of the best startups in Germany: The Hamburg-based company made it into the top 10 at the German Founders' Award 2020. Every year, the most innovative and best start-up ideas in Germany are selected in five categories at the renowned competition. The top 3 will be nominated the following week and the winner will be announced in September.

Mindpeak is already one of the best startups in Germany: The Hamburg-based company made it into the top 10 at the German Founders' Award 2020. Every year, the most innovative and best start-up ideas in Germany are selected in five categories at the renowned competition. The top 3 will be nominated the following week and the winner will be announced in September.

“I am very happy about this great nomination. The fact that we have come this far is not only an award for our innovative products for AI-assisted cancer diagnosis, but primarily for our competent and creative team. I would like to thank everyone for their committed work, especially in these challenging times, ”said founder and managing director Felix Faber in Hamburg.

Mindpeak was founded two years ago by Felix Faber and Dr. Tobias Lang and has developed AI software to increase the productivity of pathologists in clinical routine and to enable more precise cancer diagnoses. Mindpeak works with renowned research institutions such as the Charité Berlin and laboratories in Hamburg and Cambridge. The software is immediately ready for use in the laboratory without extensive pre-adjustment. The first product - breast cancer quantification software - is already on the market. Work is currently underway to expand the product portfolio to include more types of cancer.

The Mindpeak team is made up of the world's leading AI experts and alumni from Cambridge University, UC Berkeley, SCR Princeton and TU Munich. CEO Faber is an experienced entrepreneur with a successful exit and IPO. Co-founder Dr. Tobias Lang developed deep learning solutions for large e-commerce companies that are used by millions of people every day. Both founders studied computer science and artificial intelligence.

BreastIHC can currently only be used for research purposes.

Deutscher Gründerpreis

In the News

Related reading

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.
In the News
8 min read

Mindpeak in Oncology Times

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.

We’re proud to see our VP Precision Medicine, Patrick Frey, featured in Oncology Times sharing his perspective on one of oncology’s most urgent challenges – achieving true equity in biomarker testing.

As Patrick notes, the conversation must move from if to how. The science and technology already exist; now it’s about ensuring every patient, everywhere, can access and benefit from them.

At Mindpeak, we believe AI-powered pathology can help close that gap – supporting faster, more consistent insights that make precision medicine truly accessible.

In the News
8 min read

AI-Enabled Pathology: De-risking Oncology Drug Development

We are delighted to share that Aurélie Fugon, VP Predictive AI Solutions at Mindpeak, is featured in Life Science Daily News.

In her article, Aurélie outlines how AI-supported biomarker-driven strategies can reduce variability in pathology, improve the consistency of patient selection and help de-risk late-stage trials.

All key enablers of more reliable, data-rich clinical decision-making. With Aurélie’s leadership, we’re strengthening collaborations with pharma, biotech and clinical partners to help bring reproducible, scalable biomarker assessment into real-world research settings, shaping the future of predictive AI in precision oncology.

Read the full article here: https://lifesciencedaily.news/ai-enabled-pathology-de-risking-oncology-drug-development/

In the News
8 min read

United by Unique: Advancing Personalised Cancer Care on World Cancer Day

Every person with cancer is unique. So is every diagnosis - and every pathology sample that informs it.

This year’s World Cancer Day theme continues the focus on United by Unique, highlighting the importance of early detection, equitable access, and truly personalised care. It is a powerful reminder that behind every case is an individual with distinct biology, circumstances, and needs.

At Mindpeak, we believe precision medicine should be a right, not a privilege. Scientific and technological advances have transformed what is possible in cancer diagnostics. The challenge now is ensuring these innovations reach patients in ways that reflect their individuality.

Advanced AI models in digital pathology can help bridge this gap. By accelerating insights from complex tissue data and supporting clinicians with consistent, high-quality analysis, AI contributes to faster, more precise and more personalised decision-making.

On World Cancer Day, we stand with the global community in raising awareness and championing approaches that put people first. When we see the person before the disease, we move closer to a future where every individual’s uniqueness is recognized - and reflected - in their care.

Ready to advance your diagnostics

Connect with our team to explore how precision pathology works in your setting